CELZ
Creative Medical Technology Holdings Inc (CELZ)
Healthcare • NASDAQ • $2.31+1.76%
- Symbol
- CELZ
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.31
- Daily Change
- +1.76%
- Market Cap
- $8.54M
- Trailing P/E
- N/A
- Forward P/E
- -1.62
- 52W High
- $6.25
- 52W Low
- $1.50
- Analyst Target
- $20.00
- Dividend Yield
- N/A
- Beta
- 1.85
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a re…
Company websiteResearch CELZ on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.